糖肾安对高糖环境下人肾系膜细胞HO-1、VEGF表达的影响Effect of Tangshen'an on the Expression of HO-1 and VEGF in Human Renal Mesangial Cells Under High Glucose
刘桐菊;李都;王镁;
摘要(Abstract):
目的观察糖肾安含药血清对高糖环境下培养的人肾系膜细胞血红素加氧酶-1(heme oxygenase-1, HO-1)、血管内皮生长因子(vascular endothelial growth factor, VEGF)表达的影响。方法选用SPF级雄性Wistar大鼠制备不同质量浓度的糖肾安含药血清,并在高糖环境下培养人肾系膜细胞。实验随机分6组,正常组在正常糖浓度下培养,其余5组(模型组、糖肾安低、中、高剂量组、厄贝沙坦组)在高糖浓度下培养。培养结束后进行实时荧光定量聚合酶链式反应(quantitative real time PCR, qRT-PCR)、蛋白免疫印迹法(Western blot)检测高糖环境下人肾系膜细胞HO-1的m RNA及蛋白表达变化,采用酶联免疫吸附测定(ELISA)检测高糖环境下肾系膜细胞上清液中VEGF的质量浓度。结果各给药组HO-1的m RNA及蛋白表达较模型组显著上调(P <0.01),VEGF的质量浓度显著下降(P <0.01)。结论糖肾安干预糖尿病肾病(diabetic kidney disease, DKD)的作用机制可能与上调HO-1的表达,降低VEGF质量浓度有关。
关键词(KeyWords): 糖肾安;糖尿病肾病;血红素加氧酶-1;血管内皮生长因子
基金项目(Foundation): 辽宁省自然科学基金项目(201602493)
作者(Author): 刘桐菊;李都;王镁;
Email:
DOI: 10.13463/j.cnki.jlzyy.2019.10.022
参考文献(References):
- [1]ZHANG L, LONG J, JIANG W, et al. Trends in Chronic Kidney Disease in China[J]. N Engl J Med, 2016, 375(9):905.
- [2]姚佳,乔迪,郭鑫,等.桑叶中1-脱氧野尻霉素对糖尿病肾病大鼠的治疗作用[J].中国临床药理学与治疗学, 2018,23(5):517-523.
- [3]徐双双,宋志霞,杨芦蓉,等.黄葵胶囊联合缬沙坦治疗糖尿病肾病的临床效果及对HIF-1α和VEGF水平的影响[J].中药材, 2016, 39(12):2885-2888.
- [4]DESHANE J, CHEN S, CABLLERO S, et al. Stromal cellderived factor 1 promotes angiogenesis via a heme oxygenase1-dependent mechanism[J]. Journal of Experimental Medicine, 2007, 204(3):605-618.
- [5]JOZKOWICZ A, AT K W A, HUK I, et al. Effect of prostaglandin-J(2)on VEGF synthesis depends on the induction of heme oxygenase-1[J]. Antioxid Redox Signal,2002, 4(4):577-585.
- [6]李都,姚雨杉,张雪辰,等.糖肾安对高糖环境下人肾系膜细胞Nrf2/ARE通路的影响[J].中国实验方剂学杂志,2017(24):159-163.
- [7]谭颖颖,张楠,张琪.六味地黄丸含药血清减弱高糖环境下肾系膜细胞的增殖和炎性因子表达[J].中国实验方剂学杂志, 2016(1):103-107.
- [8]PFAFFL M W.A new mathematical model for relative quantification in real-time RT-PCR[J]. Nucleic Acids Research, 2001, 29(9):2002-2007.
- [9]戴宁,张煜,马捷,等.糖尿病肾病的中医治疗近况[J].吉林中医药, 2018, 38(12):1492-1495.
- [10]杨芳,赵磊,慕杨娜,等.从气虚毒瘀探讨自噬在糖尿病肾病中的作用[J].长春中医药大学学报, 2019, 35(2):208.
- [11]严倩华,邹燕勤.国医大师邹燕勤教授从脾肾论治糖尿病肾病[J].南京中医药大学学报, 2018(2):109-111.
- [12]刘红.补肾温阳、活血化瘀法治疗糖尿病肾病临床观察[J].山西中医, 2018, 34(1):11-12.
- [13]王镁,韩波.糖肾安对Ⅳ期糖尿病肾病尿蛋白排泄影响的临床观察[J].中医药学报, 2007, 35(2):60-61.
- [14]郭维文,黎帅,陈玲玲,等.黄芪甲苷对糖尿病肾病大鼠肾脏的保护作用及其机制[J].中国病理生理杂志, 2014,30(2):351-354.
- [15]李会芳,程生辉,赵换.丹参注射液辅助治疗糖尿病肾病有效性及安全性的系统评价[J].中国实验方剂学杂志,2013, 19(6):353-358.
- [16]林子桐,张超,沈雪梅.糖尿病肾病发病机制研究进展[J].中国药理学与毒理学杂志, 2014, 28(5):765-773.
- [17]SDINGH D K, WINOCOUR P, FARRINGTON K. Oxidative stress in early diabetic nephropathy:fueling the fire[J].Nature Reviews Endocrinology, 2011, 7(3):176.
- [18]SCHEIERMANN J, KLINMAN D M. Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer[J]. Vaccine, 2014,32(48):6377-6389.
- [19]HUBER T B, WALZ G, KUEHN E W. mTOR and rapamycin in the kidney:signaling and therapeutic implications beyond immunosuppression[J]. Kidney International, 2011, 79(5):502-511.
- [20]DULAK J, CISOWSKI J, LOBODA A, et al. Role of hypoxia inducible-factor-1 and heme oxygenase-1 in hypoxiaand hydrogen peroxide-induced VEGF synthesis[J].Cardiovascular Pathology, 2004, 13(3):125-126.